Studies how melanoma spreading under the skin changes over time
Studies skin melanoma nodules that spread away from the original tumor in adults.
Key facts
- Who runs it
- Yana Najjar
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 24 Feb 2021
- Expected to end
- 31 Aug 2029
- Type of study
- Observational
- Treatments tested
- Pimonidazole
- Record updated
- 11 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma who have at least two in-transit lesions at different distances from the first tumor, and whose lesions can be biopsied.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Melanoma (skin, mucosal or uveal) with at least two in-transit lesions at distinct distances from the primary site. A diagnosis of in-transit disease by the treating melanoma oncologist is enough.
- Earlier treatment
- People can be on treatment or not yet treated.
Main reasons for not taking part
- In-transit disease that the treating doctor says cannot be biopsied
- Known long-term immune suppression (for example remicade, mycophenolate, methotrexate, prednisone above 20 mg daily)
- Known HIV, hepatitis B or hepatitis C infection
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Be willing and able to provide written informed consent for the trial
- Be ≥ 18 years of age on day of signing informed consent
- A histological diagnosis of melanoma and at least two in-transit lesions at distinct distances from the primary site. Patients may be enrolled on the basis of a diagnosis of in-transit disease by a treating melanoma oncologist
- Cutaneous, mucosal or uveal melanoma are permitted
- Patients may be on treatment or treatment naïve
- Female patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days from the time of pimonidazole administration
Who cannot take part
- Subjects with in-transit disease that is not amenable to biopsy per the treating physician are excluded
- Subjects who are known to be HIV+, Hep B or Hep C positive
- Subjects with known chronic immunosuppression (such as biologic agents like remicade, mycophenolate, methotrexate, prednisone >20 mg daily)
Where in United States
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Amy Rose, RN, BSNTaking people
About the trial
What the trial wants to find out
Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted. The complexity and heterogeneity of patient and disease characteristics, including the location and number of ITMs presents a barrier to a one size fits all treatment approach. Treatment of patients with limited regional disease remains challenging. Patients are typically treated with a combination of surgery, regional therapy, systemic therapy. Data on the management of ITMs is limited, even with the availability of immunotherapy (IMT). This study will use the unique etiology of ITMs to facilitate the understanding of how individual lesions metabolically and immunologically evolve as they move away from the primary tumor site. It is hypothesize that as ITMs move away from the primary melanoma site each will harbor progressively hypermetabolic tumor cells and a harsher microenvironment.
The group in the trial
- Pimonidazole
Single dose of 0.5 gm/m\^2 of pimonidazole (approximately 13 mg/kg)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
- Plain-language title
- Studies how melanoma spreading under the skin changes over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 June 2026